Addressing challenges in mRNA drug development and manufacturing
The rapid development and approval of COVID-19 vaccines spurred renewed interest in mRNA technology, but despite its advantages, specific challenges still exit:
- Optimizing mRNA stability and protein expression
- Developing production and purification processes
- Designing an efficient therapeutic delivery vehicle
- Balancing the innate immune system response
- Obtaining the intended therapeutic response
Read the following interactive article to explore these challenges and their potential solutions.
White Paper from 
If your Download does not start Automatically, Click Download Whitepaper